I wonder if any gamblers noticed my post 334 on the GMC thread yesterday.
It looks as though bottom fishing can sometimes pay off.

very true, i notice that Fidelity Investments have another million and a half declared today. Wonder if they will put in a bid for a buy out soon haveing accumulated such a big lump of ELA?

yep seen that ...very sneakily gobbling up stock without many people noticing ...something is going on ...the only thing is there are so many "men behind the curtain" with this stock that nobody knows what the hell is going to happen ..

I just know that i will be buying on anything under 11 euro ...trust the science ...

Fidelity announced an increase in its elan stake to 14.08% today. Whats their game? is its holding purley for a client, as it does hold stakes in a number of companies? Or is it more molvelant, possibly holding for a client who is considering a buy out?

One guy even speculates on ADVFN that it is buying on behalf of Philips and a bid for Elan will come within two months. I dare say all will be revealed but the mystery is very perplexing, all good fun!

something is definately afoot news soon i feel. dont ask me why just a hunch.

Hope you're right!

well it may not have been news directly about Tysabri, but the announcement last week about Elans nano technology being used as the drug delivery method for EntreMed cancer treatment is certainly welcome, and has provided a friday boost for elan.

Goodbody says: Drug delivery partner patent progress.
Analyst: Ian Hunter
EntreMed, a Baltimore-based biotechnology company, has been awarded a patent for the method of using 2ME2, its lead drug for the treatment of cancer and non-cancer diseases, such as rheumatoid arthritis. This follows on from the award of a patent covering the composition of highly purified 2ME2 as well as the method of obtaining the compound. In January, Elan signed an agreement with EntreMed for the latter to licence Elan's nano-crystal technology, incorporating it into the drug (also known as Panzem) to create a liquid formulation. Panzem is currently in Phase II trials for treating cancer and at the preclinical stage in rheumatoid arthritis.

At least i think thats the reason :)

not such a good day or so for Elan PLC was trying to figure out why the price has fallen by the ammount it has after building up such a good rise over the last couple of weeks. I found this article that perhaps explains it, maybe????

http://www.newstarget.com/020315.html

as you can see from reading it it seems like another piece of well timed opinion designed to hurt elan and tysabri, i wonder wether it is sponsered by Teva or another such rival pharma company. On reading I thought it seemed like another pretty useless bit of subjective comment by the doctor in question., and the reporter for news target jumped on the band wagon with the scaremongering jheadline:

STANFORD DOCTORS SPOTLIGHT FATAL FLAW IN MULTIPLE SCLEROSIS DRUG TRIAL

all very good if your looking for an attention grabbing headline but the content really does leave alot to be desired. Oh well guess its just another case of rivals attempting to bring down Tysabri. Boy they must be scared at the prospect of tysabri actually being the blockbuster it surley must be given a bit of time, just goes to prove i suppose now is a good time to top up :) Maybe even theres is more news from elan around the corner and this is designed to head it off at the pass so to speak! ;)

sorry article just a rehash of old story pre fda approval. need some positve elan news

Just thought i would share some news about elan....its more a personal thing than a market thing but may be relevant....London tysabri dosing restarts this month, This is the continuation of the trial i was on for the past 3 ish years, which was stopped whenb the bad news about PML happened.

I can only assume the restart means that UK availability is up and running and the trial continuation was afterall a condition of the FDA and euro counterparts granting a licence for remarketing of this future block buster drug. guess it all takes time to get things going again and rest assured I shall be asking my neuros on wednesday what their views on the drug and its future are.

will post more wed night.

Thanks for the update Crippy

hi all not posted since i recieved first infusion, had to go through the new protocol as specified with tysabris reintroduction, mri scan, neuro testting etc. The short version is that it all worked out very well and trial runs for 12 months, hope that the people at NICE allow it to be perscribed, fingers crossed.

Anyway during the infusion, which takes an hour I did not have much chance to speak to the doctor at lenght about what the future of the drug was in her opinion, she was very busy as you might imagine, but I did ask how many of the original trial patients had taken up the oppertunity to take tysabri again and the answer was all but one of the 600 or so patients chose tom take the drug. So all the talk in the news about tysabri having a low take up and doctors wouldnt prescribe it is all a bunch of rubish according to the prof in charge of the trial i am on, who unequivically said he would prescribe it without hesitation.

So my opinion is buy now! Price has been brought down by negative publicity and many neysayers all out to damage Tysabri sales and patient confidence which of course affects Elan. todays price close below pre approval level prices. I topped up again today.

Thanks for the info Crippy. I would be buying more also if I had the funds, this share has been preforming disappointingly recently, but I still believe it's a long term winner, your added info on take up has increased my confidence!

Follow the man chaps, follow Mr Wright and get its right.

UK healthcare products developer Maelor is buying Acorus Therapeutics and expects full-year results for the year to 31 March to beat market expectations.

Maelor (MLR) shares added 11.8%, but by 2 pm were just 4% higher at 13.25p, up 0.5p which gives the AIM-listed company a market value of 4.54 million.

The company, which recently moved its offices to Chester from Wales, said the positive trading trend its cited when it reporting its interim results in November has been sustained into the last quarter of the financial year and as a result, the company anticipates a significant reduction in losses for the second half of the financial year. It didnt give specific figures.

Sales of Volplex, a plasma substitute that was Maelors first commercial product, continued to grow during the six-month period, as did sales of its catheter flushing devices, Maelor says in a trading statement.

First listed on the London Stock Exchange in 1997, Maelor has struggled in recent years to become profitable. In October 2005, five months after reporting pre-tax losses of 814,244 for the year to 31 March, the companys board brought in Tim Wright, at that time a 39-year-old vice president of international marketing at Dublin-based Elan, the publicly-traded biotechnology company.

yup its a winner alright, so much going for elan so many non believers must be sick they missed the boat, financial data coming at end of july....hope to see considerable tysabri uptake as docs and patients gain confidence, although any neuro who knows anything about ms knows this is a drug that is head and shoulders above the competition. hence the decision by NICE to allow funding recently!....plus the altheimers drug continues to reach its goals. futures sure looking up 30+ by 2008....good luck all! recent dip just consolidation, good time to get more i reckon!

ELA tanked this morning ,then recovered a bit before 14.00hours,any views.

Whats the chances With elans share price to rally withinn the next few months?

Video presentation with Eland Oil & Gas (AIM-ELA)
Les Blair, Chief Executive Officer
AIM newcomer Eland Oil & Gas, which raised £118 million through its September IPO, is developing OML 40 in the rich Niger Delta are of Nigeria

Click the link below:

http://www.brrmedia.co.uk/event/106553/les-blair-chief-executive-officer

Nice graph recently, benefiting from the increase in the price of oil.

Opuama-10 Update
Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, through its joint-venture subsidiary Elcrest Exploration and Production Nigeria Ltd ("Elcrest"), is pleased to announce the following update on the Opuama-10 well on Opuama Field, OML 40.

Opuama-10 has been drilled to a total true vertical depth of 8,121 feet, measured depth of 10,135 feet. The rig is currently cementing 9-5/8 casing which will complete today. The well encountered six oil-bearing reservoirs. Total net pay, in the six oil-bearing reservoirs, is 307 feet apparent vertical thickness.

The short string will be completed on the D1000 reservoir with 32 feet of perforation interval. The long string will be completed on the D5000 reservoir from 50 feet of perforation interval. Following completion, under the regulatory guidelines the Opuama production team will conduct a Maximum Efficient Test ("MER Test") incrementally testing the well at increasing choke sizes. It is expected that, following completion of the MER Test, initial gross production from Opuama-10 will be in line with previous guidance, at between 4,000 and 6,000 bopd (1,800 - 2,700 bopd net to Elcrest), with total production from Opuama field expected to reach 30,000 bopd (13,500 bopd net to Elcrest).

George Maxwell, CEO of Eland, commented:
"We are delighted with the significant amounts of net pay encountered by Opuama-10 and look forward to both another strong production performance following completion and testing and reaching our near-term target of producing 30,000 barrels of oil per day from Opuama field.

"The Company continues this exciting period through the second half of 2018 as our active drilling programme will increase production and generate significant revenues for Eland. We look forward to updating our stakeholders in due course."

Commencement of Ubima Appraisal
Eland Oil & Gas PLC (AIM: ELA), an oil & gas production and development company operating in West Africa with an initial focus on Nigeria, through its subsidiary Wester Ord Oil & Gas Nigeria Limited, partnered with All Grace Energy Limited, is delighted to confirm that the appraisal of Ubima field has commenced with the Deutag T-57 land rig re-entering the Ubima-1 well which has been suspended since discovery by SPDC in 1963. The Company has a 40% equity interest in the Ubima field.

A dual string completion is planned for Ubima-1 on four different reservoirs, namely on the D1000 (at 4,908 feet subsea ("ftss")), E1000/E2000 (at 6,778 ftss) and F7000 (at 9,244 ftss). The programme includes two Drill Stem Tests (DST's) on the E1000/ E2000 and D1000 prior to running the dual completion with the objective to obtain accurate fluid, pressure and production data for each separate reservoir. Thereafter extended production testing is planned, which will serve as a solid basis for the full field development plan of the Ubima field.